Amendments to the Claims:

Listing of Claims:

Claim 1 (original): A method of treating a warm-blooded animal having a proliferative disease comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl- piperazino-methyl)-benzoylamido]-2-methylphenyl}4-(3- pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor, in a quantity which is jointly therapeutically I effective against a proliferative disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 2 (original): The method according to claim 1, wherein the proliferative disease is leukemia or Imatinib-resistant leukemia.

Claim 3 (original): A method of treating a warm-blooded animal having leukemia, particularly an Imatinib-resistant leukemia, comprising administering to the animal at least one hypusination inhibitor, in a quantity which is therapeutically effective against leukemia and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 4 (original): A combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]- 2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

Claim 5 (original): Combination according to claim 4 wherein the compound (a) is used in the form of its monomethanesulfonate salt.

Claim 6 (currently amended): Combination according to claim 4 ~~or 5~~, which is a combined preparation or a pharmaceutical composition.

Claim 7 (currently amended): A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a proliferative disease of a combination according to claim 4 ~~or 5~~ and at least one pharmaceutically acceptable carrier.

Claims 8-12 (canceled)

Claim 13 (currently amended): ~~A method, a~~The combination[[,]] ~~a composition or a use according to any one of claims 1 to 10~~according to claim 4, in which the combination partners (a) and (b) are administered in synergistically effective amounts.

Claim 14 (currently amended): A commercial package comprising a combination according to ~~any one of claims 4 to 7~~claim 4, together with instructions for simultaneous, separate or sequential use thereof in the delay of progression or treatment of a proliferative disease.

Claim 15 (currently amended): ~~A~~ The method[[,]] ~~a combination, a composition, a commercial package or a use according to any one of claims 1 to 14~~according to claim 1, in wherein the hypusination inhibitor is selected from the group consisting of deferoxamine, ciclopirox, deoxyspergualin, deferiprone and GC-7.

Claim 16 (currently amended): ~~A~~ The method, ~~a combination, a composition, a commercial package or a use according to any one of claims 1 to 14~~according to claim 1, in wherein the hypusination inhibitor is 4-[3,5-bis(2- hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid.

Claim 17 (currently amended): ~~A~~ The method[[,]] ~~a combination, a composition, a commercial package or a use according to any one of claims 1 to 14~~according to claim 1, in wherein the hypusination inhibitor is ciclopirox.